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Disclaimer 
This report was sponsored by the European Medicines Agency in the context of the Benefit-risk 
methodology project and the views expressed are those of the authors. Any reference to products is 
for research and example purposes only, and is not intended to be an accurate reflection of the data 
submitted. The information contained in this report, including any reference to specific products, does 
not represent the views of the Committee for Medicinal Products for Human Use (CHMP) and was not 
taken into account by the CHMP during the scientific assessment of marketing authorisation 
applications. An opportunity for public consultation will be given in the future prior to the adoption of a 
final position.  
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Benefit-risk methodology project 
Work package 4 report: Benefit-risk tools and processes 
Report by the EMA Benefit-Risk Methodology Project Team 
1.  Introduction 
The main objective of the EMA Benefit-Risk Methodology Project [1] is the development and testing of 
tools and processes for balancing multiple benefits and risks, which can be used as an aid to informed, 
science-based regulatory decisions about medicinal products. The project consists of five consecutive 
work packages. The first work package reported on the current practice of benefit-risk assessment in 
the centralised procedure for medicinal products in the EU regulatory network [2]. The report of that 
work package described processes at the six participating agencies, all of which effectively serve the 
centralised procedure, but in different ways. 
The second work package examined the applicability of three frameworks and 18 quantitative 
approaches for assessing the benefit-risk balance [3]. We found that decision analysis [4], the applied 
technology that arose from decision theory [5], can provide a theoretically-sound basis for quantifying 
favourable and unfavourable effects, including their clinical relevance and associated uncertainties, on 
a common scale that shows the balance between benefits and risks. We proposed taking forward an 
elaboration of one framework, PrOACT-URL [6], which is based on experience in applying decision 
analysis. We also recognised the potential for supplementing decision analysis modelling with five 
other approaches: probabilistic simulation, Markov processes, Kaplan-Meier estimators, QALYs and 
conjoint analysis.  
Support for our view about combining methodologies came in the summer of 2010 when four post-
graduate students from the London School of Economics studying operational research and decision 
sciences modelled four drugs previously approved by the EMA. A variety of model combinations were 
used, all were based on decision theory. 
The experiences of the students contributed to work package 3, field testing of models for five drugs 
that were then under review by the CHMP [7]. Working with teams of four to six assessors in the 
National Competent Authorities (NCA), we found that multi-criteria decision analysis (MCDA) models 
were directly relevant to the issues faced by the teams. We completed a model for each team on-the-
spot in less than one working day, as a separate exercise from the scientific assessment.  
Participants were given a 20-item questionnaire at the start and end of each workshop to determine 
how the modelling approach compared to the usual process of preparing an assessment report. For all 
20 questions, on average, the group modelling was rated higher. In particular, participants gave higher 
ratings for the modelling approach’s ability to test easily the impact of different perspectives on the 
benefit-risk balance, provide a means to see the impact of uncertainty, provide a clear and overt 
structure, combine evidence with judgements of clinical relevance, and make assumptions, multiple 
objectives and trade-offs explicit. 
Overall, the field trials demonstrated the feasibility of a workshop approach to assessing the benefit-
risk balance of a medicinal product, guided by a framework and a quantitative model. The findings of 
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the Benefit-Risk Project through Work Package 3 were published in Drug Discovery Today—Technology 
[8]. 
2.  Recommended Tools and Processes 
The task of Work Package 4 was to synthesize information from the field test and develop a benefit-
risk tool and process that can add value in other domains. At the start of the work package, it was 
clear that MCDA would be the most relevant tool (though occasionally a decision tree might be more 
appropriate, especially when the problem is dominated by uncertainty), and that the PrOACT-URL 
framework could provide a useful guide to the steps in determining the benefit-risk balance of a 
medicinal product. 
The report for WP3 [7] recognised that a complete quantitative model might not be necessary to assist 
regulators in assessing a drug. That report suggested two gradations of assistance, assuming that the 
assessment is not so obvious that no help is needed: (1) applying the PrOACT-URL model with no 
quantitative modelling may be sufficient, or (2) developing a simple MCDA model following the eight 
steps (which are consistent with PrOACT-URL) explained in chapter 6 of Multi-Criteria Analysis: A 
Manual [9]; no special software other than Excel is required.  
In short, a full MCDA model would be most useful for difficult or contentious cases. These could arise 
when the benefit-risk balance is marginal and could tip either way depending on judgements of the 
clinical relevance of the effects, favourable or unfavourable, and in the case of many conflicting 
attributes. 
We also see a key role for quantitative modelling for European regulators as they devise plans for 
implementing the new European Community pharmacovigilance directive [10, 11]. The process of 
monitoring the benefit-risk balance of a medicinal product post-approval could be supported in 
complex or marginal cases if a quantitative model was available. As new data are received it would be 
possible to update the model with the new information to see if the benefit-risk balance has changed. 
The remainder of this report explores the development of the PrOACT-URL framework since Work 
Package 3, discusses the importance of the Effects Table, and emphasises the value of the graphical 
displays as produced for the five models in WP3. 
2.1.  PrOACT-URL framework 
This extends the work begun in the WP2 report from the EMA’s Benefit-Risk Project. The current 
version, shown in Appendix 5.1, is useful as a framework for evaluating the benefit-risk profile, 
whether or not a quantitative model is created. Its use is illustrated in detail in the Appendix. 
2.2.   Effects Table 
Step 6 of the PrOACT-URL model suggests creating an Effects Table, detailed in Appendix 5.2. The 
table displays all the favourable and unfavourable effects that assessors consider as influencing the 
benefit-risk balance, along with definitions of the effects, the unit of measurement for each effect with 
the plausible range of data, and the measured data (pooled or separately for each clinical trial) 
associated with the medicinal product and any comparators, including confidence intervals where 
appropriate. A final column in the table is reserved for brief comments about uncertainties remaining in 
the minds of assessors. 
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The table provides a compact display which enables a reader quickly to see what effects and 
accompanying information were taken into account in evaluating the benefit-risk balance of the drug. 
2.3.  MCDA modelling 
The theory of modelling decisions with multiple objectives was introduced in 1976 by Keeney and 
Raiffa [12], who extended decision theory to allow consideration of decision outcomes that are multi-
attributed. It is this theory that admirably serves the multiple criteria that must be considered in 
judging the benefit-risk balance of a medicinal product. 
In its additive form, which is suitable for most drug-approval decisions, it is fairly easy to create an 
MCDA model in Excel, particularly for the simpler representations as mentioned above. However, 
providing good sensitivity analysis capabilities allied to effective graphical displays of results is usually 
best accomplished using specialised software, such as VISA1, Logical Decisions2 or Hiview33. 
2.4.  Graphical displays 
The five models reported in WP3 were created using Hiview3, software that was originally developed at 
the London School of Economics in the early 1980s. It was designed to be used in a group setting, and 
provides extensive graphical displays of results.  
Appendix 5.4 shows three graphical displays based on the five drugs modelled in WP3. The first display 
gives overall scores for the alternatives, with stacked bar graphs showing the separate contribution of 
benefit and safety. The second display shows how the overall benefit-risk difference between two 
alternatives, e.g. a drug and the placebo, is made up of the separate weighted differences on the 
effects. For example, if the drug scores overall five points higher than the placebo, then that difference 
is broken down into the ‘part score differences’ contributed separately by each effect. The third graph 
indicates how robust the overall result is to changes in the weights on each of the individual effects. 
The computer changes the current cumulative weight on each effect over its entire possible range from 
0 to 100, and notes whether at any stage a different overall result occurs. A red bar shows that a 
slight change of less than 5 points can change the result; a yellow bar, 5 to 15 points results in a 
change; while a green bar requires a change of more than 15 points. No coloured bar indicates that 
the overall result is unaffected by any weight from 0 to 100. Thus, a display that shows just a few 
green bars provides a robust result; substantial shifts in the data or in the judged clinical relevance of 
the effects would be required before the overall benefit-risk balance would favour a different option. At 
the other extreme, many red bars would indicate a delicately-balanced result. 
We believe that these three types of graphs could greatly increase the transparency and 
communicability of results to non-technical and technical readers. 
These graphs can be created in a similar way with any specialised software. 
3.  Future Applications 
After adoption of the current WP, the project will enter into WP 5 in the form of a pilot/training phase 
focused on the Effects Table (ET). In this context, the project team will produce a template/guidance in 
preparing an ET to be incorporated under the benefit-risk section of the Rapporteur’s and CHMP 
                                                     
1
 Available at http://www.visadecisions.com/ 
2
 Available at http://www.logicaldecisions.com/home.htm  
3
 Available at http://www.catalyze.co.uk  
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assessment reports. This initial pilot phase will last for six months and upon completion the ET will be 
revised based on the experience gained from this period. 
Depending on the outcome of the pilot phase and with the agreement of the CHMP, a public 
consultation phase will be initiated that will be concluded with a workshop. A final methodology will be 
agreed by EMA based on the received feedback.
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5.  Appendix 
5.1.  PrOACT-URL Framework 
 
The 12-step PROACT-URL framework shown here is based on a generic framework for decision making, as explained in Hammond JS, Keeney RL, Raiffa H, 
Smart Choices: A Practical Guide to making Better Decisions, Boston, MA: Harvard Business School Press; 1999.   
The first two columns below show how the generic framework can be adapted to drug decision making.  The third column has been completed to show where 
the information is currently available in the EPAR. The key document accessed here for measurable data was the EPAR (additional data would be available to 
regulators from the Application). However, different judgments and sources could be used for different stakeholders, e.g., drug developers, regulators, 
health technology assessors, prescribers, patients.  
 
 
STEP DESCRIBE Notes 
PROBLEM 
1. Determine the nature 
of the problem and its 
context. 
 
 
 
 
 
 
 
 
 
 
 
2. Frame the problem. 
 
The medicinal product (e.g., new or marketed chemical or 
biological entity, device, generic). 
Indication(s) for use. 
The therapeutic area and disease epidemiology 
The unmet medical need, severity and morbidity of 
condition, affected population, patients’ and physicians’ 
concerns, time frame for health outcomes.  
The decision problem (what is to be decided and by whom, 
e.g., industry, regulator, prescriber, patient) 
 
Whether this is mainly a problem of uncertainty, or of 
multiple conflicting objectives, or some combination of the 
two, or something else (e.g., health states’ time 
progression). 
The factors to be considered in solving the problem (e.g., 
study design, sources and adequacy of data, disease 
epidemiology, presence of alternative treatments). 
 
 
 
 
 
 
 
 
 
 
 
Usually it is a mixture of favourable effect size,  unfavourable 
effect seriousness and their uncertainties. 
 
 
Ideally, only factors that make a difference to a decision need 
be included. 
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STEP DESCRIBE Notes 
OBJECTIVES 
3. Establish objectives 
that indicate the overall 
purposes to be 
achieved. 
 
4. Identify criteria for 
a) favourable effects 
b) unfavourable effects  
 
The aim (e.g., to evaluate the benefit-risk balance, to 
determine what additional information is required, to assess 
change in the benefit-risk balance, to recommend 
restrictions). 
 
A full set of criteria covering the favourable and 
unfavourable effects (e.g., endpoints, relevant health 
states, clinical outcomes).  An operational definition for 
each criterion along with a measurement scale with two 
points defined to encompass the range of performance of 
the alternatives (not just reported measures of central 
tendency, but also confidence intervals).  Considerations of 
the clinical relevance of the criteria—some are of more 
concern to decision makers than others. 
 
 
 
 
 
 
Establishing two points on each measurement criterion 
facilitates scaling of the alternatives. Usually, data are reported 
only for the alternatives considered, but quantitative modelling 
requires definitions of two points on each measurement scale: 
e.g., lowest and highest practically-realisable measures.  
Quantitative weights assigned to the scales are based on 
considerations of relevance, which may not be documented, in 
which case the relevant stakeholders or key players can provide 
the information. 
ALTERNATIVES 
5. Identify the options 
to be evaluated against 
the criteria. 
 
Pre-approval: dosage, timing of treatment, drug  vs. 
placebo and/or active comparator; the decision or 
recommendation required (e.g., approve/disapprove, 
restrict, withdraw). 
Post-approval: do nothing, limit duration, restrict indication, 
suspend. 
 
Provide a clear definition of each option. 
CONSEQUENCES 
6. Describe how the 
alternatives perform for 
each of the criteria, i.e., 
the magnitudes of all 
effects, and their 
desirability or severity, 
and the incidence of all 
effects. 
 
The consequences separately for each alternative on each 
criterion (e.g., efficacy and safety effects that are clinically 
relevant, positive and negative health outcomes), 
summarised in an ‘Effects Table’ with alternatives in 
columns and criteria in rows.  Qualitative and quantitative 
descriptions of the effects in each cell, including statistical 
summaries with confidence intervals, and references to 
source data, graphs and plots.  
 
This information rarely appears in one place, so it is necessary 
to search for the information. If more than one study is 
reported, are decisions to be based on a single ‘best’ study or 
on combined data? Is a meta-analysis available? Can the effects 
table be populated with the results from several studies? Head-
to-head comparisons are not necessarily needed for quantitative 
modelling. Report missing data. A quantitative model will 
require judgements of value functions, which express the clinical 
relevance of the data. 
TRADE-OFFS 
7. Assess the balance 
between favourable and 
unfavourable effects. 
 
The judgement about the benefit-risk balance, and the 
rationale for the judgement.   
 
A quantitative model will also require judgements of weights 
associated with the criteria. 
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STEP DESCRIBE Notes 
 
At this point, only issues concerning the favourable and unfavourable effects, and their balance, have been considered.  The next three 
steps are relevant in considering how the benefit-risk balance is affected by taking account of uncertainties. 
 
UNCERTAINTY 
8. Report the 
uncertainty associated 
with the favourable and 
unfavourable effects. 
 
 
9. Consider how the 
balance between 
favourable and 
unfavourable effects is 
affected by uncertainty. 
 
The basis for and extent of uncertainty in addition to 
statistical probabilities (e.g., possible biases in the data, 
soundness and representativeness of the clinical trials, 
potential for unobserved adverse effects) 
 
 
The extent to which the benefit-risk balance in step 7 is 
reduced by considering all sources of uncertainty, to 
provide a benefit-risk balance, and the reasons for the 
reduction. 
 
 
Incidence data, reported at step 6 in the effects table, provide 
information relevant to the probabilities of realising the effects. 
 
 
 
 
Judgement plays a key role. 
A quantitative model will explore in sensitivity analyses and 
scenario analyses (or by explicitly incorporating probability 
distributions in the model) the effects on the overall benefit-risk 
balance of all sources of uncertainty. 
RISK TOLERANCE 
10. Judge the relative 
importance of the 
decision maker’s risk 
attitude for this product. 
 
11. Report how this 
affected the balance 
reported in step 9. 
 
 
Any considerations that could or should affect the decision 
maker’s attitude toward risk for this product (e.g., orphan 
drug status, special population, unmet medical need, risk 
management plan). 
 
The basis for the decision maker’s decision as to how 
tolerable the benefit-risk balance is judged to be (taking 
into account stakeholders’ views of risk?). 
 
Some idea of the risk tolerance can be inferred from any report 
of step 9—how the favourable-unfavourable effects balance was 
affected by uncertainty. Another key role for judgement. 
 
 
LINKED DECISIONS 
12. Consider the 
consistency of this 
decision with similar 
past decisions, and 
assess whether taking 
this decision could 
impact future decisions. 
 
How this decision, and the value judgements and data on 
which it is based, might set a precedent or make similar 
decisions in the future easier or more difficult. 
 
As all decisions are based not only on evidence, but also 
interpretations of that evidence that invoke value judgements 
and beliefs about uncertainty, decision makers may wish to 
reflect on whether those judgements and beliefs are consistent 
across similar past decisions, allow future changes and can be 
defended. 
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5.2.  Effects Table: Examples 
 
In the modelling of five drugs in WP3, a major problem was establishing what favourable and 
unfavourable effects should be modelled. The guideline to decide what to include is simple: include 
only those effects that have an appreciable effect on the benefit-risk balance. Clinical judgement is 
required to apply the guideline, and even then it may be necessary to be over-inclusive initially so 
that the effects can be explored, and those that don’t affect the benefit-risk balance can then be 
ignored in making the final judgement. 
Each effect requires a precise definition, but this may not be reported in assessment reports. 
Making these explicit facilitates interpretation of the data, and enables non-specialists to 
understand what was being measured. Establishing measurement scales and defining their units 
provides a context that further aids interpretation of the data by providing an indication of the 
expected range of measured data. Thermometers in offices and homes are restricted in their 
range, in part so that a meaningful change in temperature can be observed. An increase in a 
favourable effect might be interpreted differently if a change of 3 points occurred on a 10-point 
scale rather than a 100-point scale. 
Another reason for establishing ranges is to facilitate quantitative modelling. The relative 
importance of effects is judged by comparing effect swings from worst to best on these scales, 
which is easier than comparing differences between the effects of a drug and a comparator. 
With the effects and their measurement scales defined, it follows that the data for all the options 
can then be identified. Options will include the target drug, and at least one comparison, often a 
placebo and/or other treatments. An option might include more than one dose of the drug, 
restricting an indication of the drug, limiting the duration of administering the drug, or any other 
action. 
Finally, the Effects Table provides a place to summarise the remaining uncertainties about how 
effects might influence the benefit-risk balance. 
The following steps are illustrated for Benlysta and Caprelsa. 
1. Identify only those favourable and un-favourable effects relevant to the B-R balance. 
It may be helpful to cluster the favourable effects under the headings of Primary and Secondary 
Endpoints, and unfavourable effects under Adverse Events and Serious Adverse Events. Criteria 
within a cluster are typically more similar to each other than criteria between clusters. 
2. Provide descriptions of the effects. These should include footnotes and references to 
documents that elaborate the descriptions sufficiently that they could be understood by a non-
expert. 
3. Define the measurement scales. The range should encompass measured values that could 
realistically be expected to extend from worst to best. This is explained in footnote (1) under each 
table. 
4. Identify the options. These can include the drug with different doses, a placebo, a 
comparator, and actions to restrict or limit.  
5. Display the data. Multiple studies could be displayed as separate rows, but it would be more 
helpful to provide some sort of statistical summary (e.g., pooled data or a simple weighted average 
with weights proportional to each study’s sample size, but reduced for poor studies or possible 
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biases in the data). Show confidence intervals, if available. Data from different sources could be 
flagged with footnotes if the extra information is relevant to the overall benefit-risk judgement. 
6. Note remaining effect uncertainties. A short description of the reason for each uncertainty, 
accompanied by a reference to a relevant source document if available, is sufficient.
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Table 1. Hypothetical example of an Effects Table for Benlysta (belimumab, treatment of systemic lupus erythematosus) / Based on the EPAR 
EMEA/H/C/002015 published on 09/08/2011 
Effects Name Description Best1 Worst Units Placebo2 10 
mg2 
1 mg2 Uncertainties 
(See EPAR ¶2.8) 
F
a
v
o
u
r
a
b
le
 E
ff
e
c
ts
 
(p
o
o
le
d
 d
a
ta
 b
a
s
e
d
 o
n
 t
h
e
 E
P
A
R
) 
S
L
E
 R
e
s
p
o
n
d
e
r
 I
n
d
e
x
  
(
S
R
I
)
 
SLEDAI 
% Improved  4 
Percentage of patients with at least 
4 points’ reduction in SLEDAI3 
100 0 % 41 53 48 Approved only for 
patients with high 
disease activity. 
Uncertainties 
remain about 
optimal treatment 
duration, 
maintenance doses, 
treatment holidays 
and rebound 
phenomenon. 
PGA 
% no worse 
Percentage of patients with no 
worsening in Physician's Global 
Assessment4 (worsening = an 
increase of less than 0.3 points)  
100 0 % 66 75 76 
PGA 
Mean score 
Overall mean change of PGA score 
from baseline for the study 
population 
1.0 0 Difference 0.44 0.48 0.45 
BILAG A/B Percentage of patients with no new 
BILAG3 A/2B 
100 0 % 69.0 75.2 70.1 
S
e
c
o
n
d
a
r
y
 
E
n
d
p
o
in
ts
 
CS Sparing Percentage of patients that reduced 
the dose of corticosteroids by more 
than 25% and to less than 7.5 
mg/day 
100 0 % 12.3 17.5 20.0 Support from the 
analyses of the 
secondary 
endpoints is weak 
for the overall 
population 
Flare rate Number of new BILAG A cases per 
patient year 
0 5 Number 3.51 2.88 2.90 
QoL Mean change in the total score of SF 
36 (Short Form) 
0 100 Difference 3.5 3.4 3.7 
U
n
fa
v
o
u
r
a
b
le
 
E
ff
e
c
ts
 
Potential SAEs Potential for developing tumour, 
opportunistic infections or PML 
100 0 Judgement 100 0 90 The mechanism of 
action could 
increase potential 
for developing 
infections. 
Infections Proportion of patients with serious 
infections that are life-threatening 
0 10.0 % 5.2 5.2 6.8 
Sensitivity 
Reaction 
Proportion of patients with 
hypersensitivity reactions at any 
time in the study 
0 2.0 % 0.10 0.40 0.30 
(1) Best and Worst: For similar scales, the most preferred and least preferred values that would be realistically realisable (e.g., 0 to 100% for both SLEDAI 
and PGA scales). For dissimilar scales, a range that facilitates comparing the relative importance of the scales (e.g., Infections 0-10%, and Sensitivity 
Reaction 0-2%). 
(2) Treatment effect estimates 
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(3) Scales defined in Grossman, J. and C. P. Gordon (2007). Clinical Indices in the Assessment of Lupus. Dubois' Lupus Erythematosus, 7th Ed. D. J. Wallace 
and B. H. Hahn. Philadelphia, PA, Lippincott Williams & Wilkins: 920-932. SLEDAI (Systematic Lupus Erythematosus Disease Activity Index) is a score that 
represents disease activity as judged by physicians for 24 items associated with standard weightings that are summed to give an overall score ranging from 
1 to 105. BILAG (British Isles Lupus Assessment Group) consists of 86 items that represent a physician’s judged or measured activity in eight organ-based 
systems. A weighted scoring system based on intent to treat provides an overall score ranging from 0 to 72. BILAG A is associated with severe disease, 
BILAG B with less active disease. 
(4) The PGA scale used here is a 0-10 scale with 10 being worst. However, the scale is reported to range from 0 to 3 in some publications.
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Table 2. Hypothetical example of an Effects Table for Caprelsa (vandetanib, treatment of inoperable thyroid cancer) / Based on the EPAR EMEA/H/C/002315 
published on 02/03/2012 
 Name Description Best1 Worst Units Placebo2 300 
mg2 
Uncertainties 
F
a
v
o
u
r
a
b
le
 
E
ff
e
c
ts
 
P
r
im
a
r
y
 
E
n
d
p
o
in
t 
Progression-
free survival 
Hazard Ratio 
Date of randomization to the date of objective 
progression or death (blinded independent 
review) 
0 1 unitless 1 0.46 Only a very low number of 
patients with definite RET 
negative status at baseline 
S
e
c
o
n
d
a
r
y
 
E
n
d
p
o
in
ts
 
Progression-
free survival 
(median) 
Date of randomization to the date of objective 
progression or death (Weibull model) 
60 0 months 19.3 30.5 
Objective 
Response 
(RECIST) 
Proportion of complete or partial responders (at 
least a 30% decrease in the sum of the longest 
diameter of target lesions compared to 
baseline) 
 
100 0 % 13 45 
U
n
fa
v
o
u
r
a
b
le
 E
ff
e
c
ts
 
Diarrhoea CTC3 
Grade 3-4 
Increase of ≥7 stools per day over baseline; 
incontinence; IV fluids ≥24 hrs; hospitalization; 
severe increase in ostomy output compared to 
baseline; interfering with activities of daily 
living; Life-threatening consequences (e.g., 
hemodynamic collapse) 
0 100 % 2.0 10.8 Duration of follow up in the 
pivotal study is quite short 
with regard to the need for 
long duration of treatment 
and therefore the risk of 
developing further major 
Cardiac SAEs including 
Torsades de pointe. 
QTc related 
events CTC3 
Grade 3-4 
QTc >0.50 second; life threatening signs or 
symptoms (e.g., arrhythmia, CHF, hypotension, 
shock syncope); Torsade de pointes 
0 100 % 1.0 13.4 
Infections CTC3 
Grade 3-4 
IV antibiotic, antifungal, or antiviral 
intervention indicated; interventional radiology 
or operative intervention indicated; Life-
threatening consequences (e.g., septic shock, 
hypotension, acidosis, necrosis) 
0 100 % 36.4 49.8 
(1) Best and Worst: For similar scales, the most preferred and least preferred values that would be realistically realisable. For dissimilar scales, a range that 
facilitates comparing the relative importance of the scales. 
(2) Treatment effect estimates 
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(3) NCI Common Terminology Criteria for Adverse Events v3.0; Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, 
Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006 
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5.3.  Hypothetical examples of graphical displays from the MCDA models 
in WP3 
The left column gives information about the drug. 
The ‘Added-value bars’ column shows a stacked bar graph of the final results, with the overall 
score for the alternatives given just below each bar graph. Longer green bars indicate more 
benefit, while longer red bars show more safety. The white Weight column give the sum of the 
weights on the favourable effects and the unfavourable effects, while the Cumulative Weight 
column shows those same weights normalised so their sum is 100. 
The ‘Difference display’ gives the weighted differences between the preference scores for the two 
alternatives above each display. The figures are shown graphically, the green bars giving the 
advantages of the first-named alternative, and the red bars the advantages of the other 
alternative. 
The ‘Sensitivity analysis’ display shows how the results might change if more or less weight is 
assigned to each of the effects individually. The display gives the overall most preferred alternative 
(option), while the left white field identifies criteria for which a decrease in the associated effect 
might change the result, and the right white field shows changes resulting from an increase in 
weight. A green bar shows that a change in cumulative weight of more than 15 points would be 
required for a different result; a yellow bar, a change between 5 and 15 points; a red bar, less than 
5 points; and no bars, same result whatever the weight. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The examples of graphical displays presented here were done in a research context with the 
input from the relevant Product Team and do not reflect the views of the Committee for Medicinal 
Products for Human Use. 
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Table 1: Hypothetical example of graphical displays for Vyndaqel (tafamidis meglumine) 
Drug 
Information 
Added-value bars* 
(more green, more benefit; more red, safer) 
 
Difference display 
Sensitivity analysis 
(green: robust; yellow: fairly robust; red: not 
robust) 
Tafamidis 
meglumine 
 
Indication: 
transthyretin 
amyloid 
polyneuropathy 
 
 
 
 
drug vs. placebo 
 
 
Abbreviations: 
FE: Favourable Effects, UFE: Unfavourable Effects, NIS: Neuropathic Impairment Score, mBMI: Modified Body Mass Index, RR: Percentage of 
patients with less than 2 points increase in NIS score, TTR: Transthyretin stabilasation, TQOL: Total Quality of Life, Cum Wt: Cumulative 
Weight 
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Table 2: Hypothetical example of graphical displays for Caprelsa/Zictifa (vandetanib) 
Drug 
Information 
Added-value bars* 
(more green, more benefit; more red, safer) 
 
Difference display 
Sensitivity analysis 
(green: robust; yellow: fairly robust; red: not 
robust) 
Vandetanib 
 
 
Indication: 
inoperable 
thyroid cancer 
 
 
 drug vs. placebo 
 
 
Abbreviations: 
FE: Favourable Effects, UFE: Unfavourable Effects, BRR: Biological Response Rate, PFS: Progression Free Survival, CalRR: Calcitonin Response 
Rate, ORR: Objective Response Rate, OS: Overall Survival, CEARR: Carcino-Embryonic Antigen Response Rate, TWP: Time to Worsening of 
Pain, DCR: Disease Control Rate, DOR: Duration of Response, TR: Treatment Related, AEs: Adverse Events, SAEs: Serious Adverse Events, 
QTc: QTc prolongation, Cum Wt: Cumulative Weight 
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Table 3: Hypothetical example of graphical displays for RoActemra (tocilizumab) 
Drug 
Information 
Added-value bars* 
(more green, more benefit; more red, 
safer) 
 
Difference display 
Sensitivity analysis 
(green: robust; yellow: fairly robust; red: not 
robust) 
Tocilizumab 
 
 
Extension of 
indication: 
systemic 
idiopathic 
juvenile arthritis 
 
 
 drug vs. placebo 
 
 
Abbreviations: 
FE: Favourable Effects, UFE: Unfavourable Effects, ACR: American College of Rheumatology score, AST/ALT: Aspartate/Alanine Transaminas, 
Cum Wt: Cumulative Weight 
 
 
 
 
 
 
 
 
 
  
 
Benefit-risk methodology project   
EMA/297405/2012  Page 20/20 
 
Table 4: Hypothetical example of graphical displays for Benlysta (belimumab) 
Drug 
Information 
Added-value bars* 
(more green, more benefit; more red, safer) 
 
Difference display 
Sensitivity analysis 
(green: robust; yellow: fairly robust; red: not 
robust) 
Belimumab 
 
Indication: 
systemic lupus 
erythematosus 
 
 
 
 
10mg vs. placebo, 0 weight on Potential SAEs 
 
 
 
 
Abbreviations: 
FE: Favourable Effects, UFE: Unfavourable Effects, SLE: Systemic Lupus Erythematosus, SLEDAI: SLE Disease Activity Index, CS: 
Corticosteroids, SRI: SLE Responder Index, BILAG: British Isles Lupus Assessment Group score, PGA: Physician's Global Assessment, QoL: 
Quality of Life, SAEs: Serious Adverse Events, Cum Wt: Cumulative Weight 
* Out of a possible 100 points (score of 100 on all effects, i.e., all beneficial and completely safe). 
 
